{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:20Z","timestamp":1790765240450,"version":"4.1.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Linezolid is an oxazolidinone used to treat multidrug-resistant tuberculosis (MDR-TB), including in the recently-endorsed shorter 6-month treatment regimens. Due to its narrow therapeutic index, linezolid is often either dose-adjusted or discontinued due to intolerance or toxicity during treatment, and the optimal balance between linezolid efficacy and toxicity remains unclear. India carries a significant burden of MDR-TB cases in the world, but limited information on the pharmacokinetics of linezolid and minimum inhibitory concentration (MIC) distribution is available from Indian MDR-TB patients. We enrolled participants from a tertiary care centre in Mumbai, India, treated for MDR-TB and receiving linezolid daily doses of 600 or 300\u00a0mg. Pharmacokinetic visits were scheduled between 1 and 15 months after treatment initiation to undergo intensive or sparse blood sampling. Linezolid concentration <jats:italic>versus<\/jats:italic> time data were analysed using non-linear mixed-effects modelling, with simulations to evaluate doses for different scenarios. We enrolled 183 participants (121 females), with a median age of 26 years (interquartile range [IQR] 21\u201335), weight 55.0\u00a0kg (IQR 45.6\u201365.8), and fat-free mass 38.7\u00a0kg (IQR 32.7\u201346.0). Linezolid pharmacokinetics was best described by a one-compartment model with first-order elimination allometrically scaled by fat-free mass and transit compartment absorption. The typical clearance value was 3.81\u00a0L\/h. Simulations predicted that treatment with 300\u00a0mg daily achieves a high probability of target attainment (PTA) when linezolid MIC was \u22640.25\u00a0mg\/L (61.5% of participant samples tested), while 600\u00a0mg daily would be required if MIC were 0.5\u00a0mg\/L (29% of samples). While linezolid 300\u00a0mg daily is predicted to achieve effective targets for the majority of adults with MDR-TB, it failed to achieve the therapeutic target for 21% participants. A dose of 600\u00a0mg had a PTA &amp;gt;90% for all susceptible samples, but with a higher likelihood of exceeding toxicity thresholds (31% vs 9.6%). These data suggest potential benefit to individualized dosing taking host and microbial characteristics into account to improve the likelihood of treatment efficacy while minimizing risk of toxicity from linezolid for the treatment of MDR-TB. Further prospective evaluation in different clinical settings is urgently needed to inform safety and efficacy of these lower doses.<\/jats:p>","DOI":"10.3389\/fphar.2022.1081123","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:01:06Z","timestamp":1672858866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India"],"prefix":"10.3389","volume":"13","author":[{"given":"Juan Eduardo","family":"Resendiz-Galvan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna R.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Tareq","family":"Abdelwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarir F.","family":"Udwadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tester F.","family":"Ashavaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Tornheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0138121","DOI":"10.1128\/AAC.01381-21","article-title":"Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"011744","DOI":"10.1128\/AAC.01174-20","article-title":"Population pharmacokinetics of linezolid in tuberculosis patients: Dosing regimen simulation and target attainment analysis","volume":"64","author":"Alghamdi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"59","author":"Anderson","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B4","volume-title":"NONMEM users\u2019 guides (1989\u20132013)","author":"Beal","year":"2013"},{"key":"B5","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/IJMR.IJMR_3537_20","article-title":"Linezolid-resistant mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?","volume":"154","author":"Bharadwaj","year":"2021","journal-title":"Indian J. Med. Res. Suppl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): A systematic review to establish or revise the current recommended dose for TB treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1128\/AAC.01833-10","article-title":"The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications","volume":"55","author":"Chigutsa","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jac\/dky378","article-title":"Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid","volume":"74","author":"Chirehwa","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"B11","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/aac.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","article-title":"An automated sampling importance resampling procedure for estimating parameter uncertainty","volume":"44","author":"Dosne","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3389\/fmicb.2021.655653","article-title":"Low rate of acquired linezolid resistance in multidrug-resistant tuberculosis treated with bedaquiline-linezolid combination","volume":"12","author":"Du","year":"2021","journal-title":"Front. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1002789","DOI":"10.1371\/journal.pmed.1002789","article-title":"Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies","volume":"16","author":"Garcia-Prats","year":"2019","journal-title":"PLoS Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","article-title":"Xpose - an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM","volume":"58","author":"Jonsson","year":"1998","journal-title":"Comput. Methods Programs Biomed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/BF01113502","article-title":"The importance of modeling interoccasion variability in population pharmacokinetic analyses","volume":"21","author":"Karlsson","year":"1993","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/jac\/dkg249","article-title":"Linezolid in vitro: Mechanism and antibacterial spectrum","volume":"51","author":"Livermore","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ebiom.2015.10.014","article-title":"Linezolid for treating tuberculosis: A delicate balancing act","volume":"2","author":"Maartens","year":"2015","journal-title":"EBIOM"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections","volume":"51","author":"Macgowan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1128\/AAC.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: Implications for international dosing guidelines","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dky096","article-title":"Linezolid pharmacokinetics in MDR-TB: A systematic review, meta-analysis and Monte Carlo simulation","volume":"73","author":"Millard","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","volume-title":"Guidelines for programmatic management of TB preventive treatment in India 2021 I","year":"2021"},{"key":"B28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/pharmaceutics14040753","article-title":"Model-informed precision dosing of linezolid in patients with drug-resistant tuberculosis","volume":"14","author":"Mockeliunas","year":"2022","journal-title":"Pharmaceutics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1124\/dmd.121.000776","article-title":"Linezolid metabolism is catalyzed by Cytochrome P450 2J2, 4F2, and 1B1","volume":"50","author":"Obach","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"B30","doi-asserted-by":"publisher","first-page":"ciac528","DOI":"10.1093\/CID\/CIAC528","article-title":"Bedaquiline, delamanid, linezolid and clofazimine for treatment of pre-extensively drug-resistant tuberculosis","volume":"29","author":"Padmapriyadarsini","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2334-10-83","article-title":"Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors","volume":"10","author":"Pepper","year":"2010","journal-title":"BMC Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1124\/DMD.106.013755","article-title":"Does linezolid inhibit its own metabolism?\u2014population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients","volume":"35","author":"Plock","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1111\/BCP.15368","article-title":"Parametric population pharmacokinetics of linezolid: A systematic review","volume":"16","author":"Qin","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis","volume":"50","author":"Schecter","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"B36","unstructured":"Characterizing population pharmacokinetic\/pharmacodynamic relationships in pulmonary tuberculosis infected adults using nonlinear mixed effects modelling\n            SmytheW. A.\n          Cape Town, 7700, South AfricaUniversity of Cape Town2016"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid Trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBIOM"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-04898-2_253","article-title":"Fisher Exact Test","author":"Sprent","year":"2011","journal-title":"International Encyclopedia of Statistical Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/bcp.15102","article-title":"Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients","volume":"88","author":"Tietjen","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"PA3486","DOI":"10.1183\/1393003.CONGRESS-2017.PA3486","article-title":"Linezolid experience among MDR-TB patients in Mumbai","volume":"50","author":"Tornheim","year":"2017","journal-title":"Eur. Respir. J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1183\/13993003.CONGRESS-2020.477","article-title":"Clinical features associated with linezolid resistance among multidrug resistant tuberculosis patients at a tertiary care hospital in Mumbai, India","volume":"56","author":"Tornheim","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"ofab615","DOI":"10.1093\/OFID\/OFAB615","article-title":"Increased moxifloxacin dosing among patients with multidrug-resistant tuberculosis with low-level resistance to moxifloxacin did not improve treatment outcomes in a tertiary care center in Mumbai, India","volume":"9","author":"Tornheim","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12879-019-3726-8","article-title":"Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic","volume":"19","author":"Udwadia","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"021644","DOI":"10.1128\/AAC.02164-18","article-title":"Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection","volume":"63","author":"Wasserman","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/JAC\/DKZ206","article-title":"Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa","volume":"74","author":"Wasserman","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B46","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","article-title":"Linezolid in the treatment of drug-resistant tuberculosis: The challenge of its narrow therapeutic index linezolid in the treatment of drug-resistant tuberculosis: The challenge of its narrow therapeutic index","volume":"14","author":"Wasserman","year":"2016","journal-title":"Expert Rev. Anti-infective Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1128\/AAC.00461-07","article-title":"Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption","volume":"52","author":"Wilkins","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","unstructured":"Global tuberculosis report 20202020"},{"key":"B49","volume-title":"Rapid communication: Key changes to the treatment of drug-resistant tuberculosis","year":"2022"},{"key":"B50","volume-title":"Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2018"},{"key":"B51","first-page":"98","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4, treatment : Drug-resistant tuberculosis treatment","year":"2020"},{"key":"B52","doi-asserted-by":"publisher","first-page":"106589","DOI":"10.1016\/J.IJANTIMICAG.2022.106589","article-title":"Linezolid pharmacokinetics\/pharmacodynamics-based optimal dosing for multidrug-resistant tuberculosis","volume":"59","author":"Zhou","year":"2022","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1081123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T19:01:12Z","timestamp":1672858872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1081123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":53,"alternative-id":["10.3389\/fphar.2022.1081123"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1081123","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1081123"}}